Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Real World Outcome in a Patient Cohort with Newly Diagnosed Diffuse Large B Cell Lymphoma

C De Vriendt, MD, Philip Vlummens, MD, Fritz Offner, MDhD

Blood (2017) 130 (Supplement 1): 1577.

https://doi.org/10.1182/blood.V130.Suppl_1.1577.1577

Published: 2017

Journal Articles

Exploring the Pathogenesis of Down Syndrome-Related Myeloproliferative Disorders Using iPSCs

Nishinaka Yoko, PhD, Akira Niwa, MDPhD, Mitsujiro Osawa, PhD, Akira Watanabe, PhD, Tatsutoshi Nakahata, MD PhD, Megumu K Saito, MD PhD

Blood (2014) 124 (21): 868.

https://doi.org/10.1182/blood.V124.21.868.868

Published: 2014

Journal Articles

Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?

Patrick T. Griffin, MD, Viet Q. Ho, PharmD, BCOP, William Fulp, Taiga Nishihori, MD, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2014) 124 (21): 4757.

https://doi.org/10.1182/blood.V124.21.4757.4757

Published: 2014

Journal Articles

VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients

Gabriele Buda, MD, Enrico Orciuolo, Sara Galimberti, Francesco Ghio, Mario Petrini, MD

Blood (2013) 122 (21): 5377.

https://doi.org/10.1182/blood.V122.21.5377.5377

Published: 2013

Journal Articles

Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179

Douglas A. Stewart, MD, FRCPC, Reinhard Kloiber, MD, FRCPC, Nizar Bahlis, MD, Peter Duggan, MD, FRCPC, Andrew Daly, MD, FRCPC, Christian Fibich, MD, David Blair Macdonald, MD, FRCPC, Isabelle Bence-Bruckler, MD, FRCPC

Blood (2011) 118 (21): 500.

https://doi.org/10.1182/blood.V118.21.500.500

Published: 2011

Journal Articles

A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide

Tomer M Mark, MD, MSc, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Morton Coleman, MD, David Bernstein, Faiza Zafar, PA, Usama Gergis, MD, Tsiporah B. Shore, MD, Ruben Niesvizky, MD

Blood (2010) 116 (21): 2258.

https://doi.org/10.1182/blood.V116.21.2258.2258

Published: 2010

Journal Articles

Interim Restaging FDG-PET/CT to Guide Use of High Dose Sequential Induction Therapy with Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (RDICEP) and Rituximab-Carmustine, Etoposide, Cytarabine, Melphalan (RBEAM) and Autologous Stem Cell Transplantation (ASCT) for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179.

Douglas A. Stewart, MD, FRCPC, Peter Duggan, MD, FRCPC, Nizar J Bahlis, MD, Andrew Daly, MD, FRCPC, Michelle Geddes, MD, FRCPC, Reinhard Kloiber, MD, FRCPC, Christian Fibich, MD, David Blair Macdonald, MD, FRCPC, Isabelle Bence-Bruckler, MD, FRCPC

Blood (2009) 114 (22): 3414.

https://doi.org/10.1182/blood.V114.22.3414.3414

Published: 2009

Journal Articles

Treatment of Multiple Myeloma with Vorinostat in Combination with Bortezomib: A Case Series

Amitabha Mazumder, David H Vesole, Sundar Jagannath, MD

Blood (2008) 112 (11): 5213.

https://doi.org/10.1182/blood.V112.11.5213.5213

Published: 2008

Journal Articles

DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.

Jason P. Gonsky, MD, PhD, Nikoletta Lendvai, MD, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Andrew L. Pecora, MD, Tatyana Feldman, MD, Andre Goy, MD, Stuart Goldberg, MD, David S. Siegel, MD, PhD

Blood (2007) 110 (11): 3284.

https://doi.org/10.1182/blood.V110.11.3284.3284

Published: 2007

Journal Articles

VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.

Jean-Luc Harousseau, MD, Gerald Marit, MD, Denis Caillot, MD, Philippe Casassus, MD, Thierry Facon, MD, Mohamad Mohty, MD, PhD, Frederic Maloisel, MD, Herve Maisonneuve, MD, Carine Chaleteix, MD, Lofti Benboubker, MD, PhD, Dixie-Lee Esseltine, MD, Michel Attal, MD

Blood (2006) 108 (11): 56.

https://doi.org/10.1182/blood.V108.11.56.56

Published: 2006

Journal Articles

Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin’s Lymphomas.

Chitra Hosing, MD, Rima M. Saliba, PHD, Martin Korbling, MD, Sandra Acholonu, Safa Karandish, Sergio Giralt, MD, Jo Lauppe, Marcos de Lima, MD, Grace-Julia Okoroji, Daniel R. Couriel, MD, Richard Champlin, MD, Issa F. Khouri, MD, Michele L. Donato, MD

Blood (2004) 104 (11): 2877.

https://doi.org/10.1182/blood.V104.11.2877.2877

Published: 2004

Journal Articles

Autologous Peripheral Blood Stem Cell Transplant for Relapsed or Refractory T-Cell Non-Hodgkin’s Lymphoma Results in Inferior Long Term Survival when Compared to Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphomas.

Jack W. Hsu, MD, Priya Singh, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, David S. Siegel, MD, PhD, Scott D. Rowley, MD, FACP

Blood (2004) 104 (11): 5241.

https://doi.org/10.1182/blood.V104.11.5241.5241

Published: 2004

NARROW

Real World Outcome in a Patient Cohort with Newly Diagnosed Diffuse Large B Cell Lymphoma

Exploring the Pathogenesis of Down Syndrome-Related Myeloproliferative Disorders Using iPSCs

Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?

VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients

Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier: NCT00530179

A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide

Treatment of Multiple Myeloma with Vorinostat in Combination with Bortezomib: A Case Series

DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.

VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.

Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin’s Lymphomas.

Autologous Peripheral Blood Stem Cell Transplant for Relapsed or Refractory T-Cell Non-Hodgkin’s Lymphoma Results in Inferior Long Term Survival when Compared to Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only